AKT1 and breast cancer: The results showed that LY294002 blocked the DAPT-induced phosphorylation of AKT and reduced the DAPT-increased ratio of Cdc42-GTP/Cdc42 (Figure 5, Figure S1), suggesting that DAPT activated Cdc42 through PI3K/AKT signal pathway in breast cancer cells.